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Endocannabinoids activate two types of specific G-protein-coupled receptors (GPCRs),
namely cannabinoid CB1 and CB2. Contrary to the psychotropic actions of agonists
of CB1 receptors, and serious side effects of the selective antagonists of this receptor,
drugs acting on CB2 receptors appear as promising drugs to combat CNS diseases
(Parkinson’s disease, Huntington’s chorea, cerebellar ataxia, amyotrohic lateral sclerosis).
Differential localization of CB2 receptors in neural cell types and upregulation in
neuroinflammation are keys to understand the therapeutic potential in inter alia diseases
that imply progressive neurodegeneration. Medicinal chemistry approaches are now
engaged to develop imaging tools to map receptors in the living human brain, to
develop more efficacious agonists, and to investigate the possibility to develop allosteric
modulators.
Keywords: heteromer, microglia, astroglia, M0/M1/M2 phenotype, neuroprotection, neurorestoration, GPCR,
amyotrophic lateral sclerosis
INTRODUCTION
To date only two cannabinoid receptors have been identified and completely accepted as key
members of the endocannabinoid signaling. The CB1 receptor (CB1R) is mainly expressed in the
central nervous system (CNS) (Hu and Mackie, 2015), whereas, the CB2 receptor (CB2R) is mainly
expressed in the periphery, especially in blood cells, and in blood-cell producing organs (Onaivi
et al., 1999; Atwood andMackie, 2010; Atwood et al., 2012). Other receptors, e.g., GPR55, the cation
channel TRPV1 and the nuclear receptors of the PPAR family, are also under discussion as possible
members of the endocannabinoid receptor family. CB1R and CB2R belong to the most populated
family of the human proteome, i.e., to the family of receptors coupled to heterotrimeric G proteins
(GPCRs). More specifically they are members of class A GPCRs, which are characterized by being
structurally similar to rhodopsin, for having an extracellular N-terminal domain, a seven α-helical
transmembrane domain, and a C-terminal domain of 73 (for CB1R) or of 59 (for CB2R) amino
acids. Total length of the most common1 protein products is 472 for CB1R and 360 for CB2R. The
1Isoforms of endocannabinoid receptors have been identified (details available at www.uniprot.org.)
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difference in receptor length comes from the bigger N-terminal
domain of the CB1R (116 vs. 33 amino acids).
Soon after its discovery and the realization of the relevant
role of endogenous cannabinoids, the CB1R was considered a
potential target to combat CNS diseases. In fact, the CB1R is
considered the class AGPCRmember with the highest expression
in the CNS. In sharp contrast, controversy surrounds expression
of CB2R in the CNS, and until recently this receptor was not
considered as target for neurological or neuropsychiatric diseases
(Atwood and Mackie, 2010; Atwood et al., 2012). This paper
scans the literature that supports the view that CB2R may
have now more potential than CB1R to combat some CNS
disorders, in particular those related to neuroinflammatory, and
neurodegenerative events. The paper also informs on current
developments in medicinal chemistry aspects of CB2R-based
CNS drug discovery.
BETTER PROSPECTS FOR CB2R THAN
FOR CB1R IN CNS DISEASES
GPCRs constitute the target of approximately 40% of approved
drugs. Drug development programs are still heavily relying
on the potential of GPCRs for a huge variety of diseases.
Agonists, which are able to activate the receptor and compete
with the endogenous agonist, and antagonists, which block the
receptor and impede activation by the endogenous agonist, have
therapeutic potential. However, the number of medications that
consist of GPCR antagonists outnumbers that of GPCR agonists.
In general terms, the higher success of antagonists means that
they have fewer side effects than agonists, although other causes
overlay. The endocannabinoid system is a very special case as
endogenous compounds produced by neurons and acting on
central CB1Rs are absolutely required for higher brain functions,
but any synthetic or natural (e.g., 19-tetrahydrocannabinol)
agonist reaching the brain and hitting CB1R has proved to have
psychotropic actions in animal models of disease and in humans.
Therefore, the potential of CB1Rs as targets for diseases of the
CNS, and also peripheral disorders, has been limited by the
psychoactive side effects derived from their agonists, and for
the need to consider the risk-benefit balance. In this context,
some researchers wanted to develop CB1R antagonists (including
inverse agonists) as a safer alternative in those pathologies having
an overactivity of the endocannabinoid system (e.g., obesity,
addiction, schizophrenia), although side effects were also evident
with such strategy (see below).
The first two molecules targeting CB1R that reached the
therapeutic market (in the 80s) were 19-tetrahydrocannabinol,
also known as dronabinol (marketed as Marinol R©), and nabilone
(marketed as Cesamet R©) (Figure 1), both prescribed to combat
nausea and vomiting, as well anorexia, derived from cancer,
and AIDS treatments, respectively (Green et al., 1989), but
their use was limited. By contrast, a CB1R antagonist/inverse
agonist, rimonabant (Acomplia R©), was approved in 2006 to
treat obesity, and metabolic syndrome (Carai et al., 2006) and
generated extremely high expectations. Unfortunately, the drug
had to be retired due to side effects, especially due to reports
of suicide (Sam et al., 2011). Consequently, chances, that other
CB1R selective drug may advance though regulatory bodies, and
reach the market have dramatically diminished. In this context,
the CB2R has taken the lead in the race to find novel cannabinoid-
related drugs for CNS diseases. On the one hand, CB1R is
expressed in almost any brain region, and in many neuronal
cell types, whereas CB2R expression in neurons is restricted to
few areas. Accordingly, fewer side effects are expected when
drugs are targeting receptors with restricted expression than
when drugs are targeting receptors widely expressed in the CNS.
Furthermore, CB2R are upregulated in a variety of CNS diseases
that course with activated microglia or astroglia. Then the CB2R
but not the CB1R is a promising candidate to consider in
diseases with a neuroinflammatory component. It is even possible
that the activation of CB2Rs may explain recent controversies
in relation with the consumption of cannabis as a factor
either increasing risk or preventing against spontaneous brain
insults (e.g., intracerebral hemorrhage). Recent epidemiological
studies suggest a potential protective effect of cannabis to
the modulation of C-reactive protein response in intracerebral
hemorrhage (Di Napoli et al., 2012, 2016; Alshaarawy and
Anthony, 2015), an effect that could be possibly related to CB2R
activation, although this has not been investigated. Advantages of
developing CB2R selective drugs to prevent neurodegeneration in
cases of neuroinflammation are presented later in this article.
As macrophages express CB2R and microglia is somehow
a similar cell type, these receptors were soon identified in
microglial cells, but further research demonstrated that they can
be also found in other types of glial cells (see below). There is
however, some controversy on the degree of CB2R expression
in resting vs. activated microglial cells. Also the activated
microglial phenotype is different in macrophages filtered from
the blood into the CNS and in resident microglia that becomes
activated due to, inter alia, accumulation of protein aggregates
such as alpha-synuclein, or ß-amyloid. Remarkably, (see Franco
and Fernández-Suárez, 2015 and references therein) a better
understanding of the expression and role of CB2R in the different
microglial phenotypes (M0, M1, M2) will help in designing
CB2R selective ligands able to induce the neuroprotective/anti-
inflammatory-skewed phenotype(s).
CB2R may be also expressed by CNS neurons. The role of
CB2Rs in schizophrenia, depression, food consumption, and
drug addiction has been demonstrated in different laboratories
and the results are consistent with neuronal expression of the
receptor (Onaivi et al., 2008a,b,c; Hu et al., 2009; García-
Gutiérrez et al., 2010; Ishiguro et al., 2010a,b; García-Gutiérrez
and Manzanares, 2011; Ortega-Alvaro et al., 2011; Aracil-
Fernández et al., 2012; Navarrete et al., 2012, 2013; Bahi
et al., 2014; Blanco-Calvo et al., 2014; Ortega-Álvaro et al.,
2015; Rodríguez-Arias et al., 2015; García-Cabrerizo and García-
Fuster, 2016). The receptor is significantly expressed in neurons
in the brain stem (Van Sickle et al., 2005), in the cerebellum
(Skaper et al., 1996; Ashton et al., 2006; Gong et al., 2006;
Rodríguez-Cueto et al., 2014) in the internal and the external
segments of the globus pallidus of the non-human primate
(Lanciego et al., 2011), and in the substantia nigra (in humans,
not in rodents) (García et al., 2016; Gómez-Gálvez et al., 2016).
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FIGURE 1 | Chemical structure of 19-THC, nabilone, and the CB2R ligands: JWH133, 0-1966, AEA, BCP, SMM-189, PM226,
1-butyl-3-[(cyclohexylamino)methylidene]-8-methylquinoline-2,4(1H,3H)-dione, [11C]NE40, [11C]KD2, [11C]RS-016,
2-{2-chloro-[5-(4-[18F]-d2-methoxy)-6-(4-fluorophenethylamino)-1,3,5-triazin-2-yl]phenyl}propan-2-ol.
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Different laboratories working with rodents or primates have
also identified receptor expression in neurons of the prefrontal
cortex and hippocampus (Callén et al., 2012; den Boon et al.,
2012; Sierra et al., 2015; García-Cabrerizo and García-Fuster,
2016). Expression of CB2R in the basal ganglia show promise
in Parkinson’s disease and Huntington’s chorea; the presence
of the receptor in hippocampus and prefrontal cortex makes it
attractive for Alzheimer’s disease and the expression in brain stem
and cerebellum opens novel therapeutic avenues for a variety of
diseases such as hereditary spinocerebellar ataxias. Last but not
least, the data on CB2R-mediated endocannabinoid regulation of
microglial activation makes the receptor attractive for diseases
with a neuroinflammatory component.
Cannabinoid neuroregulation is mainly based on retrograde
signaling (Alger, 2002), i.e., endocannabinoids come from post-
synaptic elements to activate presynaptic receptors. However,
postsynaptic CB2Rs have been also reported (Brusco et al., 2008).
The combination of restricted neuronal expression with the
possibility of targeting pre- or postsynaptic receptors, makes the
CB2R a really attractive target.
CB2R IN NEURODEGENERATIVE
DISORDERS. RELEVANCE OF
DIFFERENTIAL EXPRESSION OF CB2R IN
NEURAL CELLS
The preservation of neuronal integrity and survival is
one of the most promising therapeutic possibilities of
CB2R-targeting cannabinoids (Atwood et al., 2012). There
is potential in pain and in numerous acute or chronic
neurodegenerative/neuroinflammatory conditions (Jhaveri
et al., 2007; Micale et al., 2007; Campillo and Páez, 2009). The
neuroprotective potential of compounds targeting the CB2R is,
first of all, the logical consequence of their location in key cell
types (e.g., in specific neuronal subsets, activated astrocytes,
reactive microglia, perivascular microglia, oligodendrocytes, and
neural progenitor cells), and also in some structures (e.g., the
blood-brain barrier (BBB)) that are critical for the maintenance
of the CNS integrity (Amenta et al., 2012; Chung et al., 2016)
(Figure 2A). Such variety of locations enable compounds capable
to selectively activate the CB2R to exert a selective control over
the specific functions fulfilled by these cells in degeneration,
protection and/or repair (Fernández-Ruiz et al., 2014). For
example, BBB function is under the control of CB2R-mediated
signals (Fujii et al., 2014), which maintain the integrity of tight
junctions, inhibit leukocyte infiltration, and facilitate β-amyloid
clearance (Vendel and de Lange, 2014).
CB2Rs in glial cells recruited to the site of the
neurodegeneration, appear to be critical for preserving the
neuronal integrity and function (Savonenko et al., 2015). In fact,
CB2R may be absent of these cells in resting conditions, with
a weak expression in the healthy brain. As the receptors are
strongly up-regulated when glial cells are activated in conditions
of neurodegeneration (Fernández-Ruiz et al., 2007, 2015), they
have potential from a therapeutic point of view (Figure 2B).
Up-regulation may occur in both astrocytes and microglial
cells, but the CB2R-mediated signaling may vary depending
inter alia on the type of pathology and the experimental model.
CB2R-mediated neuroprotection/neurorestoration mechanisms
are of special interest in disorders that affect movement-related
areas, such as (i) Parkinson’s and Huntington’s diseases (affecting
the basal ganglia, and producing rigidity, postural instability,
bradykinesia, tremor, and chorea), (ii) autosomal dominant
spinocerebellar ataxias (affecting the cerebellum and its afferent
and efferent connections, and producing loss of balance, and
motor incoordination), and (iii) amyotrophic lateral sclerosis
(ALS) (affecting upper and lower spinal motor neurons, and
producing muscle denervation and atrophy, which results in a
progressive weakness and paralysis affecting voluntary muscles).
For example, in this last disorder, CB2Rs become up-regulated in
microglial cells recruited at the spinal cord of patients (Yiangou
et al., 2006), a fact corroborated by studies in the TDP-43 mouse
model of the disease (Espejo-Porras et al., 2015). However, apart
from microglial cells, other CB2R-positive cells were found
in this murine model (Espejo-Porras et al., 2015). In another
murine model of ALS, (the SOD-1 mouse), CB2R also become
up-regulated, but the study did not characterize the type of cell
that was expressing the receptors (Shoemaker et al., 2007).
Interestingly, microglial CB2Rs appear up-regulated in the
cerebellum of patients with different autosomal dominant
cerebellar ataxias, but such trend was also found in activated
astrocytes located in the cerebellar parenchyma and in
the periphery of blood vessels, and in certain neuronal
subpopulations (Rodríguez-Cueto et al., 2014). Similarly,
increased levels of CB2R are found in both striatal activated
astrocytes and reactive microglial cells after an insult with
malonate in rats, an experimental model of Huntington’s disease
(Sagredo et al., 2009). Although data collected fromHuntington’s
disease patients or obtained in genetic models of the disease (e.g.,
R6/1, R6/2) indicated that CB2R were located and up-regulated
only in microglial cells (Palazuelos et al., 2009), a more recent
study situated the up-regulation of these receptors in vascular
cells, not in activated glial cells, in HD patients (Dowie et al.,
2014).
In yet another neurodegenerative condition affecting the
basal ganglia circuits, (Price et al., 2009) were the first to
demonstrate up-regulation of CB2R in microglial cells recruited
at the substantia nigra in MPTP-lesioned mice. In the study it
was not addressed whether there were other CB2R-positive cells
that do not correspond to reactive microglia. We investigated
the issue in parkinsonian patients using postmortem samples and
identified such up-regulation inmicroglial cells (labeled with Iba-
1) and in another unidentified cell type (Gómez-Gálvez et al.,
2016).
CB2R has potential in demyelinating disorders (e.g., multiple
sclerosis; Molina-Holgado et al., 2002; Gomez et al., 2010,
2011). In fact, CB2R are present in oligodendrocytes, and more
importantly, in their natural precursor cells, so that theymay play
a role in their survival, proliferation, and differentiation. CB2Rs
have been also identified in neural progenitor cells, and it appears
that they can play a role in the proliferation and differentiation
of these precursors (Palazuelos et al., 2006, 2012; Goncalves
et al., 2008; Avraham et al., 2014), opening the possibility to
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FIGURE 2 | (A). Expression of CB2Rs in different neural cell types and how receptor activation may impact on cell-specific functions. (B) Cellular events that explain
the therapeutic possibilities for ligands that target CB2Rs, which are upregulated in activated glial cells.
facilitate neurorestoration by pharmacologically manipulating
this receptor. Lastly, the identification of CB2Rs in perivascular
microglial cells in the cerebellum (Núñez et al., 2004) may be
possibly related to the role attributed to these receptors at the
level of the BBB (see above).
CHALLENGES IN CB2R-BASED DRUG
DESIGN
Pharmacology of cannabinoid receptors is complex due to
the lipophilic nature of many natural and synthetic agonists.
Endogenous agonists of many class A GPCRs are hydrophilic,
which contrast with the lipophilic nature of endocannabinoids.
Pharmacological characterization by radioligand binding to
CB2R is especially complex. On the one hand, the binding site
extends deeply within the seven transmembrane domain of the
receptor, and the two available radiolabeled ligands (tritiated CP-
55940 and tritiated WIN-55212-2) do not interact with exactly
the same amino acid residues in the orthosteric center; in
particular CP-55940 does not interact with a conserved lysine
residue in the binding site (Tao et al., 1999). Furthermore, it is
hypothesized that cannabinoids may not reach the binding site
from the outside of the cells but by lateral diffusion via the lipid
bilayer of the plasma membrane (Guo et al., 2003; Makriyannis
et al., 2005; Hurst et al., 2010). These features suggest that newly
synthesized drugs or newly discovered natural cannabinoids have
qualitatively different modes of binding to CB2Rs. On the other
hand, the nonspecific binding to membranes from natural CNS
sources is high and leads to low-confidence values of the amount
of receptor in neural cells. This problem is partially solved
by performing the assays in heterologous cells expressing the
human receptor; such approach provides reliable parameters for
drug discovery. The complex pharmacology is also slowing the
discovery of allosteric centers, and accordingly, of allosteric CB2R
modulators.
GPCR pharmacology must somehow be revisited due to
the occurrence of receptor heteromers (Cordomí et al., 2015;
Franco et al., 2016). Each heteromer is unique and functionally
different from the two constituting receptors. In fact, affinity
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of agonists/antagonists may change when a given receptor
is forming heteroreceptor complexes, and more importantly,
signaling cascades may be heteromer-specific (Ferré et al.,
2009; Franco et al., 2016). Also relevant is the fact that
presynaptic heteromers seem to be different from those in
post-synaptic locations, i.e., a given GPCR may form different
heteromers in pre- or post-synaptic membranes. Cannabinoid
receptors may form a variety of heteromers with other class a
GPCRs (see www.gpcr-hetnet.com; Borroto-Escuela et al., 2014).
Interestingly, the two cannabinoid receptors may interact and
give rise to CB1R-CB2R heteromers (Callén et al., 2012; Sierra
et al., 2015). In agreement with the widespread distribution
of CB2Rs in brain and the robust expression of CB2Rs in the
globus pallidus, CB1R-CB2R heteromers are abundant in basal
ganglia output neurons; available data indicate that these CB1R-
CB2R heteromers are mainly post-synaptic. Pallidal expression
of heteromers investigated in a primate model of Parkinson’s
disease was evident in naïve and parkinsonian animals, but
it was markedly reduced in the levodopa-induced dyskinetic
group (Sierra et al., 2015). Although likely, cannabinoid-
receptor containing heteromers have not been identified and
characterized in glial cells. Heteromer expression is worth
considering on designing drugs targeting CB2R. In particular
pallidal CB1R-CB2R heteromers constitute a specific target in
Parkinson’s disease. A main advantage of selectively targeting
GPCR heteromers, i.e., to use drugs that preferentially act on
heteromer-expressing cells, is the reduction of side effects.
CB2R LIGANDS AS THERAPEUTIC
AGENTS IN CNS DISEASES
Positron Emission Tomography Reagents
for Brain Imaging
Studies of CB2R ligands as diagnostic agents for noninvasive
brain imaging have been reported. Positron emission
tomography (PET) provides a sensitive and non-invasive
imaging technique to quantify CB2R expression in the CNS.
This technique requires radioligands with high affinity and high
specificity toward CB2R. Despite the development of highly
selective CB2R ligands (Han et al., 2014), a limited number
of PET radiotracers for imaging CB2R have been reported.
Whereas, novel PET tracers for CB1R in brain imaging have
been evaluated in clinical trials, few CB2R radioligands have
been tested in humans. Few years ago, the first PET tracers
for CB2R were presented as candidates for the in vivo imaging
of neuroinflammatory events (Evens and Bormans, 2010).
Preliminary clinical assays of the first CB2R radioligand,
[11C]NE40 (Figure 1), showed appropriate fast brain kinetics in
the healthy human brain (Ahmad et al., 2013). A major challenge
is the development of CB2R PET agents with maximized
brain penetration and minimized non-specific binding. In
this sense, structural optimization of [11C]KD2 (Figure 1)
(Mu et al., 2013), a potential PET tracer with poor brain
penetration, led to the discovery of [11C]RS-016 (Figure 1),
which showed slightly improved blood-brain penetration,
and higher specific CB2R binding in murine spleen tissues
and postmortem ALS patient spinal cord tissues (Contartese
et al., 2012; Slavik et al., 2015a,b). A promising PET tracer
candidate for the in vivo evaluation of neuroinflammation
and disease progression has been recently described (Hortala
et al., 2014). A triazine derivative labeled with the long-lasting
radionucleotide fluorine-18 (Figure 1), 2-{2-chloro-[5-(4-
[18F]-d2-methoxy)-6-(4-fluorophenethylamino)-1,3,5-triazin-2-
yl]phenyl}propan-2-ol, showed in rhesus macaques, and baboons
significant brain uptake and moderate washout.
Current Medicinal Chemistry Approaches
Often, increased levels of the endogenous cannabinoid,
anandamide (AEA, Figure 1), correlate with neurodegenerative
conditions. In recent studies, AEA has been shown to alleviate
lipopolysaccharide-induced neuroinflammation in rat primary
microglial cultures. Even though AEA can activate CB1R,
CB2R, and other receptors such as GPR55, GPR18, TRPV1, or
PPARs, the anti-inflammatory effects seem to be CB2R-mediated,
although a possible functional cross talk with GPR18/GPR55
cannot be ruled out (Malek et al., 2015). Accordingly, AEA
may have potential therapeutic action on managing microglial-
derived neuroinflammation and may regulate many aspects of
the brain’s inflammatory response. However, from a medicinal
chemistry perspective, drug development is more securely based
on designing novel and selective CB2R ligands.
Despite the increasing number of reports on selective CB2R
ligands and the high expectations with this cannabinoid target,
only a few synthetic CB2R agonists have reached clinical
trials (Han et al., 2014; Aghazadeh Tabrizi et al., 2016).
CB2R agonists, namely GW842166X, CP55940, S-777469, and
JTE-907, completed phase II for treatment of different pain
conditions, but none of them has been evaluated in humans
for neurodegenerative or neuroinflammatory diseases. However,
preclinical data of CB2R agonists and inverse agonists have been
described within this therapeutic perspective (Dhopeshwarkar
and Mackie, 2014; Zhang et al., 2014).
Administration of a selective CB2R agonist, JWH-133
(Figure 1), to an animal model of brain infarction improved
infarct outcome and neurological impairment through inhibition
of different subpopulations of microglia and macrophages
(Zarruk et al., 2012). Repeated treatments with the resorcinol-
based CB2R agonist, O-1966, resulted in attenuated BBB
disruption and neuronal degeneration as shown in a traumatic
brain injury model (Amenta et al., 2012).
Trans-caryophyllene (BCP, Figure 1), a bicyclic sesquiterpene
with selective CB2R agonist properties, has been reported as a
therapeutic target for the treatment of cerebral ischemia (Guo
et al., 2014). This sesquiterpene suppressed hypoxia-induced
neuroinflammatory responses by inhibiting NF-κB activation
in microglia. Effectively, studies performed in the microglial
cell line BV-2 and in primary cultures of microglia indicated
that the inhibitory action of both cannabinoid receptor agonists
and antagonists was mediated by extracellular signal regulated
kinase 1/2 (ERK1/2), cytosolic phospholipase A2 (cPLA2), and
activation of nuclear factor kappa (NF-κB) (Ribeiro et al., 2013).
New potentially neuroprotective CB2R ligands have been
recently described. Among them, the novel CB2R inverse
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agonist SMM-189 (Figure 1) (K i(CB2) = 121 nM; K i(CB1)
= 4780 nM; EC50 = 153 nM) showed in a murine model of
mild traumatic brain injury efficacy in reducing the motor,
visual, and emotional deficits; such neuroprotection was
seemingly achieved by modulating microglial activation (Reiner
et al., 2015) and chemokine expression. Reduction of the
proinflammatory markers, oetaxin, MCP-1, and IP-10 by
SMM-189 suggests that SMM-189 would decrease infiltration of
peripheral macrophage and other cells of the immune system
implicated in neurodegeneration events (Presley et al., 2015).
The chromenoisoxazole PM226 (Figure 1) has been described
as a selective CB2R agonist (K i(CB2) = 13 nM; K i(CB1R) >
40µM; EC50 = 39 nM) with neuroprotective properties in
vitro and in vivo evaluations (Gómez-Cañas et al., 2016). In
this study, the beneficial effects of PM226 against the toxicity
caused by conditioned media generated from LPS-treated
cultured BV2 cells and exposed to a striatal neuron-derived
cell line in culture was shown to be mediated by CB2R. This
neuroprotective potential was confirmed in an in vivo model
of mitochondrial damage of striatal neurons in rats. Structure-
activity relationship studies on the quinoline-2,4(1H,3H)-dione
scaffold allowed the discovery of the CB2R agonist
1-butyl-3-[(cyclohexylamino)methylidene]-8-methylquinoline-
2,4(1H,3H)-dione (Figure 1) (EC50(CB2) = 92 nM; EC50(CB1)
> 10µM) that significantly reduced the clinical symptoms of
experimental autoimmune encephalomyelitis in a mouse model
of multiple sclerosis (Han et al., 2015). As shown by histological
analysis, oral administration of this quinoline-2,4(1H,3H)-
dione(10mg/Kg) decreased leukocyte infiltration in the spinal
cord and demyelination in white matter.
New strategies involving the targeting of CB2R have been
recently proposed for neurodegenerative and neuroinflammatory
diseases. One of them has been proposed recently after
reporting the mechanisms that could led to the beneficial
effects of 4′-O-methylhokiol (MH, Figure 1), the major bioactive
component of Magnolia grandiflora L., in animal models of
neurodegeneration (Chicca et al., 2015). MH exerts dual actions
on the endocannabinoid system by acting as CB2R modulator
and COX-2 substrate-specific inhibitor.
Another strategy that needs to be explored is targeting
CB2R homo o heterodimers. Homobivalent and heterobivalent
ligands have been explored for several GPCRs such as opioid
(Fulton et al., 2010), dopamine (Gogoi et al., 2012), or histamine
receptors (Birnkammer et al., 2012). CB1R homobivalent and
heterobivalent ligands have been designed and reported in the
literature (Nimczick and Decker, 2015). In what concerns CB2R
dimers, the first structurally bivalent compounds was designed
and synthesized in 2014 (Nimczick et al., 2014). Unfortunately,
these molecules have less activity and selectivity compared to
their monomeric compound. Bivalent molecules showed to be
weak antagonists/inverse agonists of CB1 and CB2 receptors
whereas the monomeric parent was selective CB2R agonist
(Nimczick et al., 2014). It appears that the development of
bivalent drugs for CB2Rs is still a complex task as commented
very recently (Glass et al., 2016). Reported bivalent CB1 receptor
ligands are too short to bind both receptors simultaneously. The
strategy for CB1 or CB2 receptor dimers need to be reviewed
due to the fact that the ligand reaches the binding site through
the lipid bilayer and the linkers are unlikely to be at the external
receptor face.
Despite the promising therapeutic potential offered by CB2R
agonists, their translational success depends on overcoming some
limitations, such as immune suppression upon chronic use- or
pro-inflammatory actions. There is growing evidence that CB1Rs
are subject to ligand-biased signaling (Khajehali et al., 2015).
However, ligand-biased signaling profiles of ligands at CB2R are
still under scrutiny; certainly, upon validation, they could open
new therapeutic approaches. For example, the endocannabinoid
2-arachidonoylglycerol is very potent activating the ERK1/2-
MAPK pathway at low concentration, whereas the inhibition
of the adenylyl cyclase and calcium pathways needs higher
concentrations (Dhopeshwarkar and Mackie, 2014). In the
near future allosteric modulation at CB2R may offer a novel
therapeutic approach as allosteric modulators may both fine-
tune the receptor response and minimize side-effects. Signaling-
specific allosteric modulation as well as orthosteric probe
dependence at CB1R is currently under intense focus (Morales
et al., 2016). In what concerns the CB2R, positive and negative
CB2R allosteric modulators still need to be discovered.
TARGETING CB2R IN
NEURODEGENERATIVE DISORDERS
As above mentioned, drugs specifically targeting CB2R in pallidal
neurons may provide symptomatic relief in Parkinson’s disease.
However, neuroprotection is more likely afforded by guiding glial
cells to protect or restore neuronal damage. The expression of
CB2R by glia enables these receptors to participate in the control
by glial cells of the neuronal homeostasis, integrity and survival,
particularly when glial cells become reactive (Fernández-Ruiz
et al., 2007, 2015). Such potential situates cannabinoid ligands
acting on CB2Rs in a promising position for being used in
neuroprotection (Figure 2B) (Fernández-Ruiz et al., 2015). Such
pharmacological manipulations may be the best way to modulate
the endogenous response provoked by these receptors, which
are up-regulated in activated astrocytes and reactive microglia
in response to inflammatory, excitotoxic and traumatic insults.
Accordingly, preserving healthy neurons, or rescuing damaged
neurons may be likely achieved by selecting the right agonist or
allosteric modulator of CB2R (see Figure 2B).
In the case of activated astrocytes, the benefits derived
from the activation of CB2R may be associated with: (i)
increasing the trophic role exerted by these glial cells,
including the supply of metabolic substrates to neurons (Köfalvi
et al., 2016); (ii) enhancing the generation of neurotrophins
(e.g., GDNF), anti-inflammatory mediators (e.g., interleukin-10,
interleukin-1 receptor antagonist), and/or pro-survival factors
(e.g., transforming growth factor-β) (Smith et al., 2000; Molina-
Holgado et al., 2003); and (iii) inhibiting the production of
chemokines (e.g., fractalkine) which contribute to neuronal
damage (Sheng et al., 2009). All these effects should be likely
dependent on the activation of CB2R, either working alone or in
conjunction with CB1R (Stella, 2010).
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Microglial cells have an added value as they are recruited to the
lesion site where they become reactive and change morphology
and molecular phenotype. Accordingly, CB2Rs are concentrated
surrounding the site of action of the therapeutic drug. The
benefits derived from targeting CB2R in activated microglia may
be associated with: i) regulation of migration and proliferation
at lesion sites (Walter et al., 2003; Carrier et al., 2004); (ii)
regulation in the production of TNF-α and other microglia-
derived neurotoxic factors (Fernández-Ruiz et al., 2007, 2015;
Stella, 2010); and (iii) regulation of the balance M1 (pro-
inflammatory) vs. M2 (neuroprotective) phenotypes (Mecha
et al., 2013; Franco and Fernández-Suárez, 2015; Malek et al.,
2015; Jia et al., 2016).
CONCLUDING REMARKS AND FUTURE
PERSPECTIVES
The aim of this article was to collect evidence generated in the
last years in support of the therapeutic potential of compounds
selectively targeting the CB2R. We placed emphasis in the
potential relevance to provoke neuroprotection/neurorestoration
in neurodegenerative disorders, particularly when activation of
glial elements and occurrence of local inflammatory events are
involved. We have compared the advantages of targeting CB2Rs
over targeting other elements of the endocannabinoid signaling,
in particular the CB1Rs. Right now there are a number of
advantages based on the biochemical and signaling properties
of CB2Rs, the characteristics of the binding site, their capability
to form heteromers, and very importantly, to their differential
expression and function depending on the CNS region and the
neural cell type. Knowledge of the exact role of CB2R in activated
glial cells will enhance the therapeutic potential of targeting these
receptors in neuroinflammatory/neurodegenerative disorders.
It would be relevant to assess which among those disorders
may receive more benefit from the targeting the receptor. Also
relevant are the new perspectives in the design and development
of novel ligands targeting the receptor. Other issues that require
additional investigation are those related to the necessary
developments to translate the preclinical potential of CB2Rs and
their ligands to the clinical scenario. This would be the major
challenge in the next 5–10 years after which the first CB2R-
based medications will, hopefully, be available. Expectations are
that new formulations of selective CB2R ligands active at the
orthosteric binding site, or acting as allosteric modulators, used
alone or in combination with other licensed medicines, will be
available to combat devastating neurological disorders such as
Alzheimer’s disease, Parkinson’s disease, ataxias or amyotrophic
lateral sclerosis.
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